Canada (Attorney General) v. Galderma Canada Inc., 2019 FCA 196
| Court | Federal Court of Appeal (Canada) |
| Case Date | June 28, 2019 |
| Jurisdiction | Canada (Federal) |
| Citations | 2019 FCA 196 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
14 practice notes
-
Table of Cases
...257, 259 Canada (Attorney General) v Galderma Canada Inc, 2019 FCA 196 ...........................................................................290, 294, 305 Canada (Attorney General) v Sandoz Canada Inc, 2015 FCA 249 , rev’g 2014 FC 501 ......................................................
-
The Best Of The Decade Canadian Patent Law In The 2010s
...be awarded as compensatory damages based on a hypothetical royalty between the parties. Canada (Attorney General) v Galderma Canada Inc, 2019 FCA 196, rev'g 2017 FC 1023. The Federal Court of Appeal granted the appeal of the PMPRB and returned to it the matter of whether the invention of Pa......
-
The Best of the Decade – Canadian Patent Law in the 2010s
...be awarded as compensatory damages based on a hypothetical royalty between the parties. Canada (Attorney General) v Galderma Canada Inc, 2019 FCA 196, rev’g 2017 FC 1023. The Federal Court of Appeal granted the appeal of the PMPRB and returned to it the matter of whether the invention of Pa......
-
Patented Medicine Prices Review Board
...5 , SOR/2022-162 [SOR/2022-162]. 11 2011 SCC 1 [ Celgene Corp ]. 12 Ibid at para 29. 13 Canada (Attorney General) v Galderma Canada Inc , 2019 FCA 196 at para 10 [ Canada (AG) v Galderma ]. 14 Alexion Pharmaceuticals Inc v Canada (Attorney General) , 2021 FCA 157 at para 49 [ Alexion 2021 F......
Request a trial to view additional results
3 cases
-
Innovative Medicines Canada v. Canada (Attorney General), 2020 FC 725
...do not abuse their statutory monopoly by charging excessive prices for those medicines (Canada (Attorney General) v Galderma Canada Inc, 2019 FCA 196 at para 10 [Galderma]). [78] While the Respondent takes issue with characterizing “excessive pricing” as abuse, arguing that patent abuse is ......
-
Air Passenger Rights v. Canada (Attorney General),
...v. Canada (Attorney General), 2017 FCA 242, 2017 CarswellNat 7140 at paras 9, 13-14, Canada (Attorney General) v. Galderma Canada Inc., 2019 FCA 196, 2019 CarswellNat 3012 at paras 1-2, 8, 24, 75, Bissessar v. Canada (Attorney General), 2019 FCA 305, 2019 CarswellNat 7639 at paras 20-24, 29......
-
Galderma Canada Inc. v. Canada (Attorney General), 2024 FC 46
...of Appeal granted the appeal and remitted the matter to the Board for redetermination (Canada (Attorney General) v Galderma Canada Inc, 2019 FCA 196 [Galderma FCA]. The Judgment of the Federal Court of Appeal reads as follows: The appeal is allowed with costs in this Court and in the Federa......
9 firm's commentaries
-
The Best Of The Decade Canadian Patent Law In The 2010s
...be awarded as compensatory damages based on a hypothetical royalty between the parties. Canada (Attorney General) v Galderma Canada Inc, 2019 FCA 196, rev'g 2017 FC 1023. The Federal Court of Appeal granted the appeal of the PMPRB and returned to it the matter of whether the invention of Pa......
-
The Best of the Decade – Canadian Patent Law in the 2010s
...be awarded as compensatory damages based on a hypothetical royalty between the parties. Canada (Attorney General) v Galderma Canada Inc, 2019 FCA 196, rev’g 2017 FC 1023. The Federal Court of Appeal granted the appeal of the PMPRB and returned to it the matter of whether the invention of Pa......
-
Federal Court of Appeal requires PMPRB to re-determine whether patent ‘pertains to’ Galderma’s DIFFERIN
...to Galderma’s DIFFERIN (0.1% adapalene): Attorney General of Canada v Galderma, 2019 FCA 196. In determining whether “an invention pertains to the medicine”, the Court held that the phrases “rational connection or nexus” or “merest slender thread” cannot supplant the statutory language, whi......
-
Federal Court Of Appeal Agrees That The PMPRB Incorrectly Applied The Patent-Pertaining Analysis
...its inquiry with a proper understanding of the invention of the 237 Patent. The case is Canada (Attorney General) v Galderma Canada Inc., 2019 FCA 196. About Norton Rose Fulbright Canada Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial......
Request a trial to view additional results
2 books & journal articles
-
Table of Cases
...257, 259 Canada (Attorney General) v Galderma Canada Inc, 2019 FCA 196 ...........................................................................290, 294, 305 Canada (Attorney General) v Sandoz Canada Inc, 2015 FCA 249 , rev’g 2014 FC 501 ......................................................
-
Patented Medicine Prices Review Board
...5 , SOR/2022-162 [SOR/2022-162]. 11 2011 SCC 1 [ Celgene Corp ]. 12 Ibid at para 29. 13 Canada (Attorney General) v Galderma Canada Inc , 2019 FCA 196 at para 10 [ Canada (AG) v Galderma ]. 14 Alexion Pharmaceuticals Inc v Canada (Attorney General) , 2021 FCA 157 at para 49 [ Alexion 2021 F......